

Above all else, we
are committed to the
care and improvement
of human life.

Confronting the Opioid Crisis: Using non-opioid alternatives to control pain

- **Rachael Duncan, PharmD BCPS BCCCP**

Objectives

- Discuss the current state of the opioid crisis and introduce the concept of “ALTO” = Alternatives to Opioids
- Review the implementation of an ED opioid-reduction process and policy
- Present the results of a pre- and post-implementation pilot study at Swedish Medical Center and other participating sites

Background

- The United States has 10% of the world's population, yet consumes more than 80% of the world's opioids
- In 2010, opioid consumption was 710 MME per person in the US on a yearly basis



Opioids DO NOT Cause Addiction

Study published in 1986

- Small (38 patients)
- Unknown selection criteria
- Not randomized, not blinded
- 2/3 of patients received 20 MME (morphine milligram equivalence)/day or less

Conclusion:

Risk of addiction when treating chronic pain was less than one percent

Pain. 1986 May;25(2):171-86

All patients have a right to pain control



The Medical Minute. The Opioid Crisis: Solutions for Colorado.
1999 Veterans Health Administration Memorandum:
Pain as the Fifth Vital Sign. March 1, 1999.

Pharmaceutical Industry

\$\$ spent in marketing and advertising of products

- **Ex: 2007**—Purdue Pharma pled guilty to federal criminal charges for misleading advertisement regarding the safety of OxyContin time release
 - **Fined:** \$600,000,000
 - **Sales:** \$22,000,000,000 over the past decade
 - **2010**—Reformulated OxyContin to make it more difficult to inject or snort



Today = Opioid Crisis



91
AMERICANS

die every day from
an **opioid overdose**
(that includes prescription
opioids and heroin).



Nearly
HALF

of all opioid overdose
deaths involve a
prescription opioid.



www.CDC.gov/drugoverdose/epidemic/

**What's the
answer?
ALTO Approach**

Alternatives To Opioids

- Multi-modal non-opiate approach to analgesia for specific conditions
- **Goals:** To utilize non-opiate approaches as first line therapy and educate our patients
 - Opiates will be second line treatment
 - Opiates can be given as rescue medication
 - Discuss realistic pain management goals
 - Discuss addiction potential and side effects of opioids




Lidocaine



- Used topically, intravenously, or as trigger point injections
- MSK, migraines, renal colic, abdominal, neuropathic
- Lidocaine patches are great for pain!
- Lidocaine IV doses \leq to 1.5 mg/kg over 10 min may be given in non-ICU areas (max 200 mg/dose)
 - When used at low doses, IV lidocaine is generally benign
 - **Caution** should be used when giving IV to patients with a severe cardiac history
 - Over 1 hour on the inpatient units




Trigger Point Injections



www.spineandpain.com

Ketamine

- Antagonizes NMDA receptors
- When using ketamine at a low dose, it is generally benign
- Used intranasally or intravenously
- Should not be used in patients with PTSD
- Can be used adjunctively with opioids to reduce opioid requirements



Ketamine

- Ketamine use is dose-dependent
- May be used for analgesia
 - Doses ≤ 0.2 mg/kg via slow IVP or IVPB over 10 min
 - Can be followed by 0.1 mg/kg/hr infusion
 - May be given in non-ICU areas
- Ketamine 50 mg IN can also be given
 - No IV access



Other Options

- **Ketorolac**

- 15 mg for everyone!
 - No difference in pain reduction with 30 vs 15 mg*
- Great for many pain indications including musculoskeletal pain and renal colic

- **Haloperidol**

- Low dose (1-2.5 mg IV)
- Great for nausea
 - Cannabinoid induced hyperemesis




Motov S. *Ann Emerg Med* 2016.

Other Options

- **Dicyclomine**

- MOA: antispasmodic and anticholinergic agent that acts to alleviate smooth muscle spasms in the GI tract
- 20 mg/kg PO/IM (NOT IV!)
- Great for abdominal pain (think cramps)
- Caution in elderly



ED Pain Treatment Pathways

Headache/Migraine

1st Line/Immediate


1 L 0.9% NS + high-flow oxygen

Ketorolac 15 mg IV

Dexamethasone 10 mg IV

Metoclopramide 10 mg IV

Trigger point injection with lidocaine 1%



2nd Line/Alternative

APAP 1000 mg PO + IBU 600 mg PO

Promethazine 12.5 mg IV OR prochlorperazine 10 mg IV

DHE 1 mg IV OR Sumatriptan 6 mg SC

Magnesium 1 g IV

Valproic acid 500 mg IV

Lidocaine 1.5 mg/kg IV



Musculoskeletal Pain

Non-IV Options

APAP 1000 mg PO + IBU 600 mg PO
Cyclobenzaprine 5 mg PO OR diazepam 5 mg PO
Ketamine 50 mg IN
Trigger point injections 1-2 mL lidocaine 1%



IV Options

Ketamine 0.2 mg/kg IV + 0.1 mg/kg/hr gtt
Ketorolac 15 mg IV
Dexamethasone 8 mg IV
Diazepam 5 mg IV



Renal Colic

1st Line/Immediate
Ketorolac 15 mg IV
Acetaminophen 1000 mg PO
1 L 0.9% NS bolus

2nd Line
Lidocaine 1.5 mg/kg IV

Alternative
DDAVP 40 mcg IN
Ketamine 50 mg IN




**Implementation:
Is this possible?**

Step 1: ID Project Champions

- ED Nursing
 - Director, charge RNs, staff
- ED Physicians
 - Director, staff
- Hospital Leadership
 - CNO, CMO, CEO
- Other Support
 - IT
 - Pharmacy
 - Quality
 - Marketing/Communication

Step 2: Provider Education

- Physicians teach physicians
 - Training sessions on trigger point injections and nerve blocks
 - Scripting on how to manage up ALTO options
- Partner with pharmacy to create opioid-free pain management orderset
 - Organized by indication
- Utilization of outpatient prescribing guidelines
 - For when discharging patients home
 - Inclusion of many oral options for each indication
- Internal publication of opioid prescribing patterns



Step 3: Nursing Education

- Nurses teach nurses – teach the teacher model
 - Utilized annual “Skills Days” to train all staff
- Learn about the new multimodal, ALTO pathways
 - Education boards
 - Weekly newsletters
 - Podcasts (see last slide)
 - Webinars
 - Badge buddies
- Be proactive with patient and family concerns
 - Begin conversation regarding best practices to manage pain
 - Manage pain control expectations – talk about realistic pain goals
 - Utilize AIDET-based scripting: “control” of pain versus “relief” of pain
 - Promote “increasing comfort”

Musculoskeletal Pain

Non-IV Therapies
APAP 1000 mg + IBU 600 mg PO
Cyclobenzaprine 5 mg OR diazepam 5 mg PO
Gabapentin 600 mg PO
Lidoderm TD patch (max 3)
Ketamine 50 mg IN
Trigger-point inj w/ lidocaine 1%



IV Therapy Options
Ketamine 0.2 mg/kg IV + 0.1 mg/kg/hr gtt
Ketorolac 15 mg IV
Dexamethasone 8 mg IV
Diazepam 5 mg IV



Step 4: Patient Education

- Patients
 - Educate patients and families on pain assessment tools
 - Provide non-pharmacologic alternatives to medication
 - Warm blankets, ice packs, dim lights, music
 - Handout educational pamphlets
 - ALTO approach to pain management
 - Risks of opioids
- Marketing
 - Reach out to community partners to promote the ALTO approach
 - Work with ED staff on creating educational boards, handouts, and signs to advertise ALTO and set expectations
 - Tell the “why”

Step 5: Pharmacy

- Policy Changes
 - Procedural Sedation
 - Ketamine dosing – clearly define analgesia vs sedation doses
 - High-risk Medication Administration
 - Lidocaine administration
 - Ketamine administration
- Smart Pumps
 - Addition of new medications – clearly label “for pain”
 - Lidocaine
 - Ketamine
- Stocking of ALTO medications

Step 6: IT & Data

- CPOE
 - Creation of ALTO-based pain management order set
 - Create order strings for unique entries – clearly label “for pain”
- Data Collection
 - Opioid and ALTO usage reports built in Meditech
 - Other reports off the dashboard to characterize patient population

Timeline for Success

6 months
prior

- Enlist project champions throughout hospital
- Work with IT to create ED ALTO order set

3 months
prior

- Begin educating nurses and physicians on new medications, orders, and scripting
- Update high risk med and procedural sedation policies

1 month prior

- Stock medications in ED
- Program smart pumps for new medications
- Marketing push to the hospital and community

<https://cha.com/wp-content/uploads/2018/01/CHA-Opioid-Checklist.pdf>

Success in Action: Swedish ED Pilot Results


Data Collection

- Implementation = September 2016
 - Compared 2016 data to 2015 data
- **Primary outcome** = change in ED IV opioid use pre- and post-implementation
 - Measured in morphine dosing equivalents
 - Per ED patient visit
- **Secondary outcome** = patient satisfaction
 - Press Ganey Scores
 - How likely are you to recommend this facility?
 - How well was your pain controlled?

**Data is not yet published

Swedish Results


Reduction of IV Opioid Usage



Mean IV MME/visit in 2015 vs 2016 = 1.9 vs 1.5 ($p=0.0146$),
a **reduction of over 20%**

Patients Receiving Opioids During ED Stay


*Total of 29,494 (14,800 in 2015, 14,694 in 2016) visits in the ED



*Almost 1000 less patients received an opioid in the ED following the initiation of opioid reduction initiatives

Press Ganey Patient Satisfaction Scores

*Patient satisfaction scores remained consistent!




***No significant difference** between 2015 and 2016 responses for each question after adjusting for age, sex, and race

State-Wide Opioid Taskforce

- Colorado Opioid Safety Collaborative
 - Colorado Hospital Association
 - Swedish Medical Center ED Opioid Reduction Pilot
 - CO ACEP Opioid Taskforce
 - https://cha.com/wp-content/uploads/2018/01/COACEP_Opioid_Guidelines-Final.pdf
 - Colorado Consortium
 - Colorado Emergency Nurses Association
- Expand Swedish pilot to 10 other ED pilot sites in CO
 - Data collection: 6 months pre- and post- implementation
 - Goal = **15% reduction** in opioid administration

Overall Results from Pilot

36%



in opioid
administration

Measured in
MEUs/1,000 ED visits
across all 10 EDs

2017 vs. 2016

31%




in ALTO
administration

35,000

fewer projected
opioid
administrations
during the pilot than
during the baseline
period

Overall Results – By Site


Percent Change from Baseline in MEUs per 1,000 ED Visits



https://cha.com/wp-content/uploads/2018/01/CHA.090-Opioid-SummitReport_web2.pdf

Statewide Pilot: Swedish Data

Reduction of Opioid Usage



****Post-pilot results show an almost 50% decrease in overall ED opioid usage since implementation of opioid-reduction initiatives in 2015**

Lessons Learned

- Change is possible!!
- Collaborate – don't feel isolated; reach out to other facilities
- Tell the “why” – have all members take ownership of the opioid crisis
- Partner with your marketing department for messaging to community
- Have a communication plan for within the facility
 - ALTOs will trickle to the inpatient side!
- Do the little things to ensure success – prelaunch checklist
- Include patients when making decisions to manage pain
- Gather metrics to show if change is effective
- Share successes with department

Other Educational Material

Opioid reduction podcasts:

<https://emergencymedicalminute.com/opioid-miniseries/>

Itunes – Emergency Medical Minute
emergencymedicalminute.com



Contact Information

Rachael Duncan, PharmD, BCPS BCCCP

Rachael.Duncan@healthonecares.com